Association Study Between C-Reactive Protein Genes and Ischemic Stroke in Japanese Subjects

American Journal of Hypertension

Volumn 19, Issue 6, 2006, Pages 593-600

  Morita, Akihiko ^a   Nakayama, Tomohiro ^a   Soma, Masayoshi ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

association study; C reactive protein; haplotype; polymorphism; single nucleotide polymorphism

Indexed keywords

C REACTIVE PROTEIN;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; GENOTYPE; HAPLOTYPE; HUMAN; JAPAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CEREBROVASCULAR ACCIDENT; FEMALE; HAPLOTYPES; HUMANS; INTRACRANIAL ARTERIOSCLEROSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS;

EID: 33646831294     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjhyper.2005.11.015     Document Type: Article

References (30)

1. Tanaka H., Ueda Y., Hayashi M., Date C., Baba T., Yamashita H., Shoji H., Tanaka Y., Owada K., and Detels R. Risk factors for cerebral hemorrhage and cerebral infarction in a Japanese rural community. Stroke 13 (1982) 62-73
2. Kannel W.B., and McGee D.L. Diabetes and cardiovascular disease. The Framingham study. J Am Med Assoc 241 (1979) 2035-2038
3. Iso H., Jacobs D.R.J., Wentworth D., Neaton J.D., and Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N Engl J Med 320 (1989) 904-910
4. Murai A., Tanaka T., Miyahara T., and Kameyama M. Lipoprotein abnormalities in the pathogenesis of cerebral infarction and transient ischemic attack. Stroke 12 (1981) 167-172
5. Wolf P.A., D'Agostino R.B., Kannel W.B., Bonita R., and Belanger A.J. Cigarette smoking as a risk factor for stroke. The Framingham Study. J Am Med Assoc 259 (1988) 1025-1029
6. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
7. Torzewski J., Torzewski M., Bowyer D.E., Frohlich M., Koenig W., Waltenberger J., Fitzsimmons C., and Hombach V. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler Thromb Vasc Biol 18 (1998) 1386-1392
8. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W., Li R.K., Dhillon B., and Mickle D.A. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 105 (2002) 1890-1896
9. Danesh J., Whincup P., Walker M., Lennon L., Thomson A., Appleby P., Gallimore J.R., and Pepys M.B. Low grade inflammation and coronary heart disease. prospective study and updated meta-analyses. Br Med J 321 (2000) 199-204
10. Ridker P.M., Stampfer M.J., and Rifai N. Novel risk factors for systemic atherosclerosis. a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. J Am Med Assoc 285 (2001) 2481-2485
11. Rost N.S., Wolf P.A., Kase C.S., Kelly H.M., Silbershatz H., Massaro J.M., D'Agostino R.B., Franzblau C., and Wilson P.W. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack. the Framingham study. Stroke 32 (2001) 2575-2579
12. Cao H., and Hegele R.A. Human C-reactive protein (CRP) 1059G/C polymorphism. J Hum Genet 45 (2000) 100-101
13. Russell A.I., Cunninghame G.D.S., Shepherd C., Roberton C.A., Whittaker J., Meeks J., Powell R.J., Isenberg D.A., Walport M.J., and Vyse T.J. Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus. Hum Mol Genet 13 (2004) 137-147
14. Brull D.J., Serrano N., Zito F., Jones L., Montgomery H.E., Rumley A., Sharma P., Lowe G.D., World M.J., Humphries S.E., and Hingorani A.D. Human CRP gene polymorphism influences CRP levels. implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 23 (2003) 2063-2069
15. Zee R.Y., and Ridker P.M. Polymorphism in the human C-reactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 162 (2002) 217-219
16. Szalai A.J., McCrory M.A., Cooper G.S., Wu J., and Kimberly R.P. Association between baseline levels of C-reactive protein (CRP) and a dinucleotide repeat polymorphism in the intron of the CRP gene. Genes Immun 3 (2002) 14-19
17. Wolford J.K., Gruber J.D., Ossowski V.M., Vozarova B., Antonio T.P., Bogardus C., and Hanson R.L. A C-reactive protein promoter polymorphism is associated with type 2 diabetes mellitus in Pima Indians. Mol Genet Metab 78 (2003) 136-144
18. van Swieten J.C., Koudstaal P.J., Visser M.C., Schouten H.J., and van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 19 (1988) 604-607
19. Haketa A., Soma M., Nakayama T., Sato M., Kosuge K., Aoi N., and Matsumoto K. Two medium-chain acyl-coenzyme A synthetase genes, SAH and MACS1, are associated with plasma high-density lipoprotein cholesterol levels, but they are not associated with essential hypertension. J Hypertens 22 (2004) 1903-1907
20. Nakayama T., Soma M., Rahmutula D., Ozawa Y., and Kanmatsuse K. Isolation of the 5′-flanking region of genes by thermal asymmetric interlaced polymerase chain reaction. Med Sci Monit 7 (2001) 345-349
21. Livak K.J., Marmaro J., and Todd J.A. Towards fully automated genome-wide polymorphism screening. Nat Genet 9 (1995) 341-342
22. Dempster A.P., Laird N.M., and Rubin D.B. Maximum likelihood from in complete data via the EM algorithm. J R Stat Soc 39 (1977) 1-22
23. Tomiyama H., Okazaki R., Koji Y., Usui Y., Hayashi T., Hori S., and Yamashina A. Elevated C-reactive protein. a common marker for atherosclerotic cardiovascular risk and subclinical stages of pulmonary dysfunction and osteopenia in a healthy population. Atherosclerosis 178 (2005) 187-192
24. Kannel W.B., Wolf P.A., Verter J., and McNamara P.M. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. J Am Med Assoc 214 (1970) 301-310
25. Tanizaki Y., Kiyohara Y., Kato I., Iwamoto H., Nakayama K., Shinohara N., Arima H., Tanaka K., Ibayashi S., and Fujishima M. Incidence and risk factors for subtypes of cerebral infarction in a general population. the Hisayama study. Stroke 31 (2000) 2616-2622
26. Wilson W.A., Gharavi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., Brey R., Derksen R., Harris E.N., Hughes G.R., Triplett D.A., and Khamashta M.A. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. report of an international workshop. Arthritis Rheum 42 (1999) 1309-1311
27. Feldmann E., and Levine S.R. Cerebrovascular disease with antiphospholipid antibodies. immune mechanisms, significance, and therapeutic options. Ann Neurol 37 Suppl (1995) S114-S130
28. Janardhan V., Wolf P.A., Kase C.S., Massaro J.M., D'Agostino R.B., Franzblau C., and Wilson P.W.F. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack. the Framingham cohort and offspring study. Stroke 35 (2004) 736-741
29. Vittecoq O., Jouen-Beades F., Krzanowska K., Bichon-Tauvel I., Menard J.F., Daragon A., Gilbert D., Tron F., and Le Loet X. Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic and anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology 39 (2000) 481-489
30. Morris R.W., and Kaplan N.L. On the advantage of haplotype analysis in the presence of multiple disease susceptibility alleles. Genet Epidemiol 23 (2002) 221-233